2seventy bio Statistics
Total Valuation
2seventy bio has a market cap or net worth of $265.62 million. The enterprise value is $332.28 million.
Important Dates
The last earnings date was Wednesday, May 7, 2025, before market open.
| Earnings Date | May 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
2seventy bio has 53.23 million shares outstanding. The number of shares has increased by 2.02% in one year.
| Current Share Class | 53.23M |
| Shares Outstanding | 53.23M |
| Shares Change (YoY) | +2.02% |
| Shares Change (QoQ) | +2.10% |
| Owned by Insiders (%) | 4.27% |
| Owned by Institutions (%) | 72.40% |
| Float | 42.70M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 5.41 |
| Forward PS | 5.58 |
| PB Ratio | 1.22 |
| P/TBV Ratio | 1.28 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 6.87 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.80, with a Debt / Equity ratio of 1.12.
| Current Ratio | 4.80 |
| Quick Ratio | 4.69 |
| Debt / Equity | 1.12 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -1.94% and return on invested capital (ROIC) is -8.11%.
| Return on Equity (ROE) | -1.94% |
| Return on Assets (ROA) | -7.49% |
| Return on Invested Capital (ROIC) | -8.11% |
| Return on Capital Employed (ROCE) | -13.53% |
| Revenue Per Employee | $744,077 |
| Profits Per Employee | -$62,954 |
| Employee Count | 65 |
| Asset Turnover | 0.10 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +14.04% in the last 52 weeks. The beta is 1.05, so 2seventy bio's price volatility has been similar to the market average.
| Beta (5Y) | 1.05 |
| 52-Week Price Change | +14.04% |
| 50-Day Moving Average | 4.70 |
| 200-Day Moving Average | 4.06 |
| Relative Strength Index (RSI) | 71.71 |
| Average Volume (20 Days) | 741,570 |
Short Selling Information
The latest short interest is 2.59 million, so 4.87% of the outstanding shares have been sold short.
| Short Interest | 2.59M |
| Short Previous Month | 3.78M |
| Short % of Shares Out | 4.87% |
| Short % of Float | 6.08% |
| Short Ratio (days to cover) | 2.44 |
Income Statement
In the last 12 months, 2seventy bio had revenue of $48.37 million and -$4.09 million in losses. Loss per share was -$0.08.
| Revenue | 48.37M |
| Gross Profit | -13.24M |
| Operating Income | -59.35M |
| Pretax Income | -156.25M |
| Net Income | -4.09M |
| EBITDA | -52.72M |
| EBIT | -59.35M |
| Loss Per Share | -$0.08 |
Full Income StatementBalance Sheet
The company has $170.38 million in cash and $239.76 million in debt, giving a net cash position of -$66.40 million or -$1.25 per share.
| Cash & Cash Equivalents | 170.38M |
| Total Debt | 239.76M |
| Net Cash | -66.40M |
| Net Cash Per Share | -$1.25 |
| Equity (Book Value) | 213.96M |
| Book Value Per Share | 4.08 |
| Working Capital | 157.19M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$54.09 million and capital expenditures -$95,000, giving a free cash flow of -$54.19 million.
| Operating Cash Flow | -54.09M |
| Capital Expenditures | -95,000 |
| Free Cash Flow | -54.19M |
| FCF Per Share | -$1.02 |
Full Cash Flow StatementMargins
Gross margin is -27.37%, with operating and profit margins of -122.71% and -8.46%.
| Gross Margin | -27.37% |
| Operating Margin | -122.71% |
| Pretax Margin | -8.46% |
| Profit Margin | -8.46% |
| EBITDA Margin | -109.01% |
| EBIT Margin | -122.71% |
| FCF Margin | n/a |
Dividends & Yields
2seventy bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.02% |
| Shareholder Yield | -2.02% |
| Earnings Yield | -1.54% |
| FCF Yield | -20.38% |
Analyst Forecast
The average price target for 2seventy bio is $6.50, which is 30.26% higher than the current price. The consensus rating is "Buy".
| Price Target | $6.50 |
| Price Target Difference | 30.26% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 18.76% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
2seventy bio has an Altman Z-Score of -1.1 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.1 |
| Piotroski F-Score | 2 |